Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)

Diagnostic Microbiology and Infectious Disease

Volumn 86, Issue 2, 2016, Pages 249-251

  Jones, Ronald N ^a   Rhomberg, Paul R ^a   Mendes, Rodrigo E ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL SKIN DISEASE; DRUG APPROVAL; DRUG SCREENING; ENTEROCOCCUS FAECALIS; FOOD AND DRUG ADMINISTRATION; IN VITRO STUDY; LABORATORY TEST; LETTER; MEASUREMENT ACCURACY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENTEROCOCCUS; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES; STANDARDS; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS; STREPTOCOCCUS; TEICOPLANIN; VANCOMYCIN;

EID: 84989875086     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.02.007     Document Type: Letter

References (17)

1. Biedenbach, D.J., Bell, J.M., Sader, H.S., Turnidge, J.D., Jones, R.N., Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 53 (2009), 1260–1263.
2. Boucher, H.W., Wilcox, M., Talbot, G.H., Puttagunta, S., Das, A.F., Dunne, M.W., Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370 (2014), 2169–2179.
3. Clinical and Laboratory Standards Institute (CLSI), M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition. 2015, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI), M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. 2016, CLSI, Wayne, PA.
5. Dalvance™ Package Insert, 2016, DurataTherapeutics U.S., Limited, Parsippany, NJ, U.S. (Available at http://content.stockpr.com/duratatherapeutics/files/docs/Dalvance+APPROVED+USPI.PDF. Accessed December 2015).
6. Dalvance™ Package Insert, 2016, DurataTherapeutics U.S. Limited, Parsippany, NJ, USA (Available at http://www.allergan.com/assets/pdf/dalvance_pi. Accessed January 2016).
7. Dunne, M.W., Sahm, D., Puttagunta, S., Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies. Ann Clin Microbiol Antimicrob, 14, 2015, 19.
8. EUCAST, EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. Available at http://www.eucast.org/clinical_breakpoints/, 2016 (Accessed January 2016).
9. Fritsche, T.R., Rennie, R.P., Goldstein, B.P., Jones, R.N., Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms. J Clin Microbiol 44 (2006), 2988–2990.
10. Jones, R.N., Streit, J.M., Fritsche, T.R., Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 23 (2004), 197–199.
11. Jones, R.N., Sader, H.S., Fritsche, T.R., Hogan, P.A., Sheehan, D.J., Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol 44 (2006), 2622–2625.
12. Jones, R.N., Flamm, R.K., Sader, H.S., Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 76 (2013), 122–123.
13. Jones, R.N., Sader, H.S., Flamm, R.K., Update of dalbavancin spectrum and potency in the USA; report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 75 (2013), 304–307.
14. Jones, R.N., Farrell, D.J., Flamm, R.K., Sader, H.S., Dunne, M.W., Mendes, R.E., Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis 82 (2015), 73–77.
15. Mendes, R.E., Castanheira, M., Farrell, D.J., Flamm, R.K., Sader, H.S., Jones, R.N., Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). J Antimicrob Chemother 71 (2016), 276–278.
16. Turnidge, J., Kahlmeter, G., Kronvall, G., Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12 (2006), 418–425.
17. Zhanel, G.G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagace-Wiens, P.R., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70 (2010), 859–886.